Eldelumab
Based on 1 Customer Validation
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.50%
- CAS No.: 946414-98-8
- Masse moléculaire:146.64 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99188
CarlumabAnti-CCL2 Antibody -
HY-P99272
UlocuplumabCXCR4 Antagonist -
HY-P9902
PembrolizumabPD-1 Inhibitor -
HY-P9913
RituximabCD20 Inhibitor -
HY-15979A
H-89 dihydrochloridePKA Inhibitor -
HY-15319
AMG 487CXCR3 Antagonist -
HY-P9905
CetuximabEGFR Inhibitor -
HY-P99189
CixutumumabAnti-IGF-1R mAb -
HY-16711
SB225002CXCR2 Antagonist -
HY-15251
ReparixinCXCR1/2 Inhibitor -
HY-10198
NavarixinCXCR1/2 Antagonist -
HY-19855
AZD-5069CXCR2 Antagonist
Activité biologique
Description
Isotype
Human IgG1(K214R) kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CXCL10/IP-10
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IP-10/CXCL10 Protein can bind Eldelumab. The EC50 for this effect is 1.68 ng/mL.
Chemical Information
-
CAS No. 946414-98-8
-
Appearance Liquid
-
Masse moléculaire 146.64 kDa
-
Color Colorless to light yellow
-
SMILES
[Eldelumab]
-
Synonyms
BMS-936557; MDX-1100
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Gupta RK, et al. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. PLoS One. 2021 Sep 28;16(9):e0257784. [Content Brief]
[2]. Asquith DL, et al. Targeting cell migration in rheumatoid arthritis. Curr Opin Rheumatol. 2015 Mar;27(2):204-11. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Eldelumab Related Classifications
HY-P99190 Related Classifications
Powered by Bioz